AngioDynamics Toekomstige groei

Future criteriumcontroles 3/6

De verwachting is dat AngioDynamics de winst en omzet met respectievelijk 95.2% en 7.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 95.5% per jaar.

Belangrijke informatie

95.2%

Groei van de winst

95.5%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	7.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	04 Oct 2024

Recente toekomstige groei-updates

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Jul 19

Recent updates

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Jul 19

Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

Jul 18

AngioDynamics: A Story To Monitor

May 14

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 09

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Apr 06

AngioDynamics: Restructuring Initiative May Not Go Far Enough

Jan 14

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Oct 12

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Mar 31

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

Oct 06

Winst- en omzetgroeiprognoses

NasdaqGS:ANGO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
5/31/2027	343	-2	N/A	N/A	1
5/31/2026	306	-28	N/A	N/A	3
5/31/2025	284	-39	N/A	N/A	3
8/31/2024	293	-243	-27	-21	N/A
5/31/2024	304	-184	-34	-28	N/A
2/29/2024	324	-192	-23	-17	N/A
11/30/2023	330	-14	-7	-3	N/A
8/31/2023	336	6	-5	-1	N/A
5/31/2023	339	-52	-4	0	N/A
2/28/2023	335	-37	-12	-7	N/A
11/30/2022	328	-33	-22	-17	N/A
8/31/2022	321	-33	-28	-23	N/A
5/31/2022	316	-27	-11	-7	N/A
2/28/2022	306	-40	-7	-4	N/A
11/30/2021	303	-38	7	11	N/A
8/31/2021	298	-34	16	21	N/A
5/31/2021	291	-32	19	24	N/A
2/28/2021	273	-169	10	16	N/A
11/30/2020	271	-171	-14	-8	N/A
8/31/2020	268	-170	-21	-13	N/A
5/31/2020	264	-167	-22	-15	N/A
2/29/2020	277	-7	0	7	N/A
11/30/2019	273	-6	27	33	N/A
8/31/2019	273	-7	36	40	N/A
5/31/2019	271	-11	34	37	N/A
2/28/2019	205	-34	33	36	N/A
11/30/2018	223	-16	28	32	N/A
8/31/2018	240	-12	26	29	N/A
5/31/2018	262	-6	N/A	41	N/A
2/28/2018	343	1	N/A	37	N/A
11/30/2017	345	-10	N/A	47	N/A
8/31/2017	347	4	N/A	51	N/A
5/31/2017	270	-7	N/A	56	N/A
2/28/2017	356	-25	N/A	55	N/A
11/30/2016	358	-27	N/A	53	N/A
8/31/2016	357	-42	N/A	48	N/A
5/31/2016	351	-44	N/A	45	N/A
2/29/2016	347	-1	N/A	37	N/A
11/30/2015	346	-6	N/A	37	N/A
8/31/2015	349	-5	N/A	25	N/A
5/31/2015	352	-3	N/A	26	N/A
2/28/2015	356	-4	N/A	25	N/A
11/30/2014	358	5	N/A	12	N/A
8/31/2014	354	4	N/A	23	N/A
5/31/2014	351	2	N/A	25	N/A
2/28/2014	346	2	N/A	26	N/A
11/30/2013	340	-3	N/A	37	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ANGO de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat ANGO de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ANGO binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ANGO ( 7.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van ANGO ( 7.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ANGO naar verwachting over 3 jaar hoog zal zijn

AngioDynamics Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 16%

No longer forecast to breakeven

AngioDynamics, Inc. Provides Earnings Guidance for the Year 2025

Consensus EPS estimates upgraded to US$0.81 loss

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Forecast to breakeven in 2027

Recent updates

AngioDynamics, Inc. Announces the Launch of an International Multi-Center Prospective Registry Study

CEO, President & Director recently bought US$121k worth of stock

Consensus EPS estimates fall by 16%

No longer forecast to breakeven

First quarter 2025 earnings: EPS misses analyst expectations

AngioDynamics, Inc. Provides Earnings Guidance for the Year 2025

New minor risk - Shareholder dilution

AngioDynamics, Inc., Annual General Meeting, Nov 12, 2024

AngioDynamics, Inc. to Report Q1, 2025 Results on Oct 03, 2024

Consensus EPS estimates upgraded to US$0.81 loss

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2027

AngioDynamics, Inc. (NasdaqGS:ANGO) announces an Equity Buyback for $15 million worth of its shares.

AngioDynamics, Inc. to Report Q4, 2024 Results on Jul 16, 2024

AngioDynamics: A Story To Monitor

CEO, President & Director recently bought US$67k worth of stock

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Price target decreased by 10.0% to US$13.50

Insufficient new directors

AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024

Angiodynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc

AngioDynamics, Inc. to Report Q3, 2024 Results on Apr 04, 2024

Angiodynamics, Inc. Announces Board Changes

Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease

AngioDynamics: Restructuring Initiative May Not Go Far Enough

AngioDynamics, Inc. Announces Manufacturing Operations Restructuring

David D. Helsel to Leave AngioDynamics, Inc. as Senior Vice President of Global Operations and R&D, Effective January 12, 2024

AngioDynamics, Inc. to Report Q2, 2024 Results on Jan 05, 2024

AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Angiodynamics, Inc. Provides Earning Guidance for Fiscal Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AngioDynamics, Inc., Annual General Meeting, Nov 14, 2023

Price target increased by 12% to US$17.33

AngioDynamics, Inc. to Report Q1, 2024 Results on Oct 04, 2023

AngioDynamics, Inc. Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

Angiodynamics, Inc. Completes Enrollment for Preserve Clinical Study

CEO, President & Director exercised options and sold US$102k worth of stock

AngioDynamics, Inc. Announces Addition of Lorinda Burgess to Board of Directors

Consensus EPS estimates fall by 52%, revenue upgraded

AngioDynamics, Inc. Provides Financial Guidance for the Fiscal Year 2024

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

AngioDynamics, Inc. to Report Q4, 2023 Results on Jul 12, 2023

New minor risk - Profitability

Merit Medical Systems, Inc. (NasdaqGS:MMSI) acquired Dialysis Product Portfolio and BioSentry Product of AngioDynamics, Inc. (NasdaqGS:ANGO) for $100 million.

Forecast to breakeven in 2026

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Price target decreased by 22% to US$20.00

Key Executive recently sold US$60k worth of stock

Price target decreased to US$24.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AngioDynamics, Inc. Reaffirms Revenue Guidance for Fiscal 2023

AngioDynamics, Inc. to Report Q2, 2023 Results on Jan 05, 2023

Price target decreased to US$26.50

Insufficient new directors

AngioDynamics, Inc. Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism

CEO, President & Director recently bought US$150k worth of stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

AngioDynamics, Inc. Reaffirms Earnings Guidance for the Year 2023

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold

AngioDynamics, Inc., Annual General Meeting, Nov 03, 2022

AngioDynamics, Inc. to Report Q1, 2023 Results on Oct 06, 2022

Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?